Selected research
Industry Research
Vitamin K Antagonists (VKA) Industry Research Report 2026
Market perspective
The global Vitamin K Antagonists (VKA) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Vitamin K Antagonists (VKA) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Vitamin K Antagonists (VKA) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Vitamin K Antagonists (VKA) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Vitamin K Antagonists (VKA) include Sanofi, Johnson & Johnson, Lilly, Pfizer, Bayer, AstraZeneca, The Medicines Company, Otsuka and Genentech (Roche), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Vitamin K Antagonists (VKA) market in terms of revenue (US$ million) and, where applicable, sales volume (W Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vitamin K Antagonists (VKA) Market by Company
Sanofi
Johnson & Johnson
Lilly
Pfizer
Bayer
AstraZeneca
The Medicines Company
Otsuka
Genentech (Roche)
Daiichi Sankyo
Bristol-Myers Squibb
Boehringer Ingelheim
Aspen
Vitamin K Antagonists (VKA) Segment by Type
Oral Vitamin K Antagonists
Injection Vitamin K Antagonists
Vitamin K Antagonists (VKA) Segment by Application
AF
ACS/MI
VTE
Others
Vitamin K Antagonists (VKA) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vitamin K Antagonists (VKA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vitamin K Antagonists (VKA) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vitamin K Antagonists (VKA).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vitamin K Antagonists (VKA) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vitamin K Antagonists (VKA) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vitamin K Antagonists (VKA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Vitamin K Antagonists
- Injection Vitamin K Antagonists
Applications
- AF
- ACS/MI
- VTE
- Others
Companies covered
- Sanofi
- Johnson & Johnson
- Lilly
- Pfizer
- Bayer
- AstraZeneca
- The Medicines Company
- Otsuka
- Genentech (Roche)
- Daiichi Sankyo
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Aspen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vitamin K Antagonists (VKA) Market Size (2021-2032)
- 2.2.2 Global Vitamin K Antagonists (VKA) Sales (2021-2032)
- 2.2.3 Global Vitamin K Antagonists (VKA) Market Average Price (2021-2032)
- 2.3 Vitamin K Antagonists (VKA) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral Vitamin K Antagonists
- 2.3.3 Injection Vitamin K Antagonists
- 2.4 Vitamin K Antagonists (VKA) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 AF
- 2.4.3 ACS/MI
- 2.4.4 VTE
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vitamin K Antagonists (VKA) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vitamin K Antagonists (VKA) Sales (W Tons) of Manufacturers (2021-2026)
- 3.3 Global Vitamin K Antagonists (VKA) Revenue of Manufacturers (2021-2026)
- 3.4 Global Vitamin K Antagonists (VKA) Average Price by Manufacturers (2021-2026)
- 3.5 Global Vitamin K Antagonists (VKA) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vitamin K Antagonists (VKA), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vitamin K Antagonists (VKA), Product Type & Application
- 3.8 Global Manufacturers of Vitamin K Antagonists (VKA), Established Date
- 3.9 Global Vitamin K Antagonists (VKA) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Vitamin K Antagonists (VKA) Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Vitamin K Antagonists (VKA) Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Lilly
- 4.3.1 Lilly Company Information
- 4.3.2 Lilly Business Overview
- 4.3.3 Lilly Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Lilly Vitamin K Antagonists (VKA) Product Portfolio
- 4.3.5 Lilly Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Vitamin K Antagonists (VKA) Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Bayer
- 4.5.1 Bayer Company Information
- 4.5.2 Bayer Business Overview
- 4.5.3 Bayer Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bayer Vitamin K Antagonists (VKA) Product Portfolio
- 4.5.5 Bayer Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca Vitamin K Antagonists (VKA) Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 The Medicines Company
- 4.7.1 The Medicines Company Company Information
- 4.7.2 The Medicines Company Business Overview
- 4.7.3 The Medicines Company Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 The Medicines Company Vitamin K Antagonists (VKA) Product Portfolio
- 4.7.5 The Medicines Company Recent Developments
- 4.8 Otsuka
- 4.8.1 Otsuka Company Information
- 4.8.2 Otsuka Business Overview
- 4.8.3 Otsuka Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Otsuka Vitamin K Antagonists (VKA) Product Portfolio
- 4.8.5 Otsuka Recent Developments
- 4.9 Genentech (Roche)
- 4.9.1 Genentech (Roche) Company Information
- 4.9.2 Genentech (Roche) Business Overview
- 4.9.3 Genentech (Roche) Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Genentech (Roche) Vitamin K Antagonists (VKA) Product Portfolio
- 4.9.5 Genentech (Roche) Recent Developments
- 4.10 Daiichi Sankyo
- 4.10.1 Daiichi Sankyo Company Information
- 4.10.2 Daiichi Sankyo Business Overview
- 4.10.3 Daiichi Sankyo Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Daiichi Sankyo Vitamin K Antagonists (VKA) Product Portfolio
- 4.10.5 Daiichi Sankyo Recent Developments
- 4.11 Bristol-Myers Squibb
- 4.11.1 Bristol-Myers Squibb Company Information
- 4.11.2 Bristol-Myers Squibb Business Overview
- 4.11.3 Bristol-Myers Squibb Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Bristol-Myers Squibb Vitamin K Antagonists (VKA) Product Portfolio
- 4.11.5 Bristol-Myers Squibb Recent Developments
- 4.12 Boehringer Ingelheim
- 4.12.1 Boehringer Ingelheim Company Information
- 4.12.2 Boehringer Ingelheim Business Overview
- 4.12.3 Boehringer Ingelheim Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Boehringer Ingelheim Vitamin K Antagonists (VKA) Product Portfolio
- 4.12.5 Boehringer Ingelheim Recent Developments
- 4.13 Aspen
- 4.13.1 Aspen Company Information
- 4.13.2 Aspen Business Overview
- 4.13.3 Aspen Vitamin K Antagonists (VKA) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Aspen Vitamin K Antagonists (VKA) Product Portfolio
- 4.13.5 Aspen Recent Developments
5 Global Vitamin K Antagonists (VKA) Market Scenario by Region
- 5.1 Global Vitamin K Antagonists (VKA) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vitamin K Antagonists (VKA) Sales by Region: 2021-2032
- 5.2.1 Global Vitamin K Antagonists (VKA) Sales by Region: 2021-2026
- 5.2.2 Global Vitamin K Antagonists (VKA) Sales by Region: 2027-2032
- 5.3 Global Vitamin K Antagonists (VKA) Revenue by Region: 2021-2032
- 5.3.1 Global Vitamin K Antagonists (VKA) Revenue by Region: 2021-2026
- 5.3.2 Global Vitamin K Antagonists (VKA) Revenue by Region: 2027-2032
- 5.4 North America Vitamin K Antagonists (VKA) Market Facts & Figures by Country
- 5.4.1 North America Vitamin K Antagonists (VKA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
- 5.4.3 North America Vitamin K Antagonists (VKA) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Vitamin K Antagonists (VKA) Market Facts & Figures by Country
- 5.5.1 Europe Vitamin K Antagonists (VKA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
- 5.5.3 Europe Vitamin K Antagonists (VKA) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Vitamin K Antagonists (VKA) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vitamin K Antagonists (VKA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vitamin K Antagonists (VKA) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vitamin K Antagonists (VKA) Market Facts & Figures by Country
- 5.7.1 South America Vitamin K Antagonists (VKA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
- 5.7.3 South America Vitamin K Antagonists (VKA) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Vitamin K Antagonists (VKA) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vitamin K Antagonists (VKA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vitamin K Antagonists (VKA) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vitamin K Antagonists (VKA) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Vitamin K Antagonists (VKA) Sales by Type (2021-2032)
- 6.1.1 Global Vitamin K Antagonists (VKA) Sales by Type (2021-2032) & (W Tons)
- 6.1.2 Global Vitamin K Antagonists (VKA) Sales Market Share by Type (2021-2032)
- 6.2 Global Vitamin K Antagonists (VKA) Revenue by Type (2021-2032)
- 6.2.1 Global Vitamin K Antagonists (VKA) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vitamin K Antagonists (VKA) Revenue Market Share by Type (2021-2032)
- 6.3 Global Vitamin K Antagonists (VKA) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vitamin K Antagonists (VKA) Sales by Application (2021-2032)
- 7.1.1 Global Vitamin K Antagonists (VKA) Sales by Application (2021-2032) & (W Tons)
- 7.1.2 Global Vitamin K Antagonists (VKA) Sales Market Share by Application (2021-2032)
- 7.2 Global Vitamin K Antagonists (VKA) Revenue by Application (2021-2032)
- 7.2.1 Global Vitamin K Antagonists (VKA) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vitamin K Antagonists (VKA) Revenue Market Share by Application (2021-2032)
- 7.3 Global Vitamin K Antagonists (VKA) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vitamin K Antagonists (VKA) Value Chain Analysis
- 8.1.1 Vitamin K Antagonists (VKA) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vitamin K Antagonists (VKA) Production Mode & Process
- 8.2 Vitamin K Antagonists (VKA) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vitamin K Antagonists (VKA) Distributors
- 8.2.3 Vitamin K Antagonists (VKA) Customers
9 Global Vitamin K Antagonists (VKA) Analyzing Market Dynamics
- 9.1 Vitamin K Antagonists (VKA) Industry Trends
- 9.2 Vitamin K Antagonists (VKA) Industry Drivers
- 9.3 Vitamin K Antagonists (VKA) Industry Opportunities and Challenges
- 9.4 Vitamin K Antagonists (VKA) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst